Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus ACTISITE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus ACTISITE.
ACTICLATE CAP vs ACTISITE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
Topical application of tetracycline hydrochloride 10 mg/g periodontal fiber. Inserted into periodontal pocket and left in place for 10 days.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
Not applicable due to local degradation; systemic half-life is negligible as tetracycline hydrochloride is not absorbed.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Primarily eliminated by phagocytic degradation at the application site; minimal systemic absorption, negligible renal or biliary excretion.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic